← Eichor
Condition: Acute Myeloid Leukemia Aml Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Acute Myeloid Leukemia Aml

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06245746Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06874257Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06232694Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy
Phase N/A · 3 location(s) · Centre Hospitalier Universitaire, Amiens · NCT03450512A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With A
Phase 2 · 19 location(s) · Shanghai Tong Ren Hospital · NCT05736965Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06511882VA vs DA for Newly Diagnosed Hig-risk AML
Phase 2/Phase 3 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT05939180MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07490288A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Phase 1 · 1 location(s) · Nanjing Chia-tai Tianqing Pharmaceutical · NCT06049667Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Phase 2/Phase 3 · 1 location(s) · M.D. Anderson Cancer Center · NCT04708054Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 2 · 1 location(s) · University of Manitoba · NCT06599762Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute M
Phase 1 · 22 location(s) · National Cancer Institute (NCI) · NCT06484062Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Im
Phase 1 · 22 location(s) · Taiho Oncology, Inc. · NCT04953910Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia
Phase N/A · 7 location(s) · Carevive Systems, Inc. · NCT05974150Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi
NA · 1 location(s) · University of Washington · NCT06710418Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06379360First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod
Phase 1 · 6 location(s) · Genmab · NCT07384715APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Phase 1 · 7 location(s) · Aptevo Therapeutics · NCT06634394Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Phase 2 · 1 location(s) · Timothy Pardee · NCT07471841A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensi
Phase N/A · 13 location(s) · AbbVie · NCT05317494Haplo-Cord HSCT for AML/MDS
NA · 4 location(s) · Fujian Medical University Union Hospital · NCT07588360Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens
Phase 2/Phase 3 · 56 location(s) · University Hospital, Angers · NCT02416388Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreat
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06827899Massage Impact on Sleep in Pediatric Oncology
NA · 2 location(s) · Children's Hospital of Philadelphia · NCT06892158MRD Response-adapted Allo-HSCT for Adverse-risk AML
NA · 1 location(s) · Peking University People's Hospital · NCT06301425A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06529250VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07028086
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.